
Delphi Diagnostics Genomic Test Predicts Paclitaxel Benefit in Breast Cancer
Patients with HR+/HER2− breast cancer showing low endocrine activity derive significant clinical benefit from weekly paclitaxel, according to a new analysis of the GEICAM/9906 trial. The findings establish Delphi Diagnostics’ Endocrine Activity Index as a predictive tool for tailoring chemotherapy regimens beyond standard recurrence risk assessments.






)















